Trial NCT03294694

View at ClinicalTrials.gov 
Org. Study IDs: 17-285

Last trial update was posted on 2022-03-31

MeSH Interventions

Fulvestrant Spartalizumab

MeSH Conditions

Breast Neoplasms Carcinoma, Ovarian Epithelial Ovarian Neoplasms

Other Conditions

HER2-Negative Breast Cancer Metastatic Epithelial Ovarian Cancer Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer

Stopping Reasons

Safety Implications

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID